Androgen News and Research

RSS

GTx reports net loss of $2.6 million for first quarter 2011

GTx, Inc. today provided a company update and reported financial results for the first quarter of 2011.

9 May 2011

Enzon first quarter adjusted loss from continuing operations decreases to $4.2 million

Enzon Pharmaceuticals, Inc. today announced its financial results for the first quarter of 2011.

7 May 2011

Ipsen first quarter sales increase 6.1% to €285.8 million

Ipsen reported today its sales for the first quarter 2011.

3 May 2011

FDA approves new targeted therapy to treat men with advanced prostate cancer

The Food and Drug Administration on Thursday approved abiraterone, a new targeted therapy in the class of androgen receptor blockers.

3 May 2011

Women with PCOS show high levels of blood markers linked with cardiovascular disease

A new study presented at the European Congress of Endocrinology shows that women with polycystic ovary syndrome show higher levels of blood markers associated with cardiovascular disease than control groups.

2 May 2011

Scripps Research receives $1.9 million NIH grant for prostate cancer study

The Scripps Research Institute and Tampa's Moffitt Cancer Center have been awarded more than $2 million to study the formation and progression of prostate cancer. Of the funds awarded, approximately $1.9 million will go to Scripps Research, with the remaining $138,380 supporting Moffitt Cancer Center work.

27 Apr 2011

Organic pollutants in flame retardents cause molecular changes in reproductive organs

Polybrominated diphenyl ethers (PBDEs) are chemicals that have been widely used as flame retardants and are now classified as persistent organic pollutants. Health concerns in humans have arisen based primarily on studies with laboratory animals exposed to high levels of PBDEs. Three commercial mixtures of PBDEs have been manufactured in or imported into the United States which include penta-, octa-, and deca-brominated diphenyl ethers (BDEs).

15 Apr 2011

Powerful natural formula is an effective treatment for men with prostate cancer

Researchers at Indiana University and Methodist Research Institute publish the dramatic effects of a natural formula against prostate cancer. This is the second in-depth study supporting the effectiveness of this formula against the disease.

7 Apr 2011

University of Houston part of multi-investigator $5.2M CPRIT award for prostate cancer research

A pair of University of Houston (UH) researchers and their colleagues will begin work to develop new methods for treating the most severe form of prostate cancer thanks to $5.2 million in grants recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).

2 Apr 2011

Study shows immune therapy can prevent pregnancy in mammals including humans

Researchers at Weill Cornell Medical College have shown that it is possible to immunize mammals to control fertility. They say their technique could possibly be used on other mammals -- including humans -- because fertility hormones and their receptors are species-non-specific and are similar in both females and males.

1 Apr 2011

Immune therapy can control fertility in mammals

31 Mar 2011

Researchers identify drug candidate that can treat prostate cancer

The best way to prevent the lethal spread of prostate cancer is by stopping cancer cell invasion of other tissues. Available treatments such as chemotherapy are toxic and can often be risky for older men, who are also most likely to get prostate cancer.

31 Mar 2011

Majority of men on ADT after prostatectomy gain weight during first year of therapy

Seventy per cent of men who received androgen-deprivation therapy (ADT) after surgery to remove their prostate gland gained significant weight in the first year, putting on an average of 4.2kg, according to a paper in the March issue of the urology journal BJUI.

11 Mar 2011

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Adamis Pharmaceuticals Corporation announced today that it has recently submitted to the FDA an Investigational New Drug application for APC-100 to treat prostate cancer.

9 Mar 2011

Ipsen, Gtx terminate collaboration for development and commercialization of toremifene

GTx, Inc. today announced that the company and Ipsen have mutually agreed to terminate their collaboration for the development and commercialization of toremifene.

2 Mar 2011

Ipsen 2010 total revenues increase 5.2% to €1,170.3 million

In 2010, Group drug sales grew 5.1% year-on-year - at constant currency - exceeding the objective set a year ago of 3.0% to 5.0%, fuelled notably by the sales of Specialty Care products throughout all the geographical regions where the Group operates.

2 Mar 2011

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Exelixis, Inc. today reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial.

18 Feb 2011

Early balding linked to prostate cancer: Study

Balding early in life causes grief for many men and now new research will cause even more alarm. Researchers have found that early balding may be liked to prostate cancer.

16 Feb 2011

Men going bald at young age more likely to develop prostate cancer in later life

Men who start to lose hair at the age of 20 are more likely to develop prostate cancer in later life and might benefit from screening for the disease, according to a new study published online in the cancer journal, Annals of Oncology today.

15 Feb 2011

Sequencing of whole prostate cancer genomes - an historic development

Today's announcement regarding the sequencing of whole prostate cancer genomes is an historic development in the fight against prostate cancer. The ability to sequence whole genomes will spare some patients from unnecessary treatments and side effects while eliminating an estimated $1.5 billion that is spent each year on overtreatment. The complete research findings will be published in the February 10 issue of Nature.

14 Feb 2011